Sanai Health Industry Group Co Ltd
01889
Company Profile
Business description
Sanai Health Industry Group Co Ltd is a pharmaceutical company. The company has three reportable segments namely Pharmaceutical products include development, manufacturing, marketing, and sales of pharmaceutical products and related software and provision of consultancy services. Finance leasing includes the provision of financial leasing services; Genetic testing and molecular diagnostic services segment. It generates maximum revenue from Pharmaceutical products segments. Geographically, it derives the majority of its revenue from the PRC.
Contact
57 Hung To Road
Unit 5, 7th Floor, Nanyang Plaza
Kwun Tong, Kowloon
Hong Kong
HKGSector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
147
Stocks News & Analysis
stocks
Avoid this overpriced ASX share
This ASX share is 84% overvalued and lacks a sustainable competitive advantage.
stocks
Markets brief: How will AI affect economic moats? Morningstar’s take on the new paradigm
A broad assessment of AI’s threats and opportunities leads to moat ratings changes for more than three dozen companies.
stocks
Baidu: Moat downgraded to none from wide; AI segment growth to offset search decline in long \run
We’ve also lowered our fair value estimate of Baidu stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,924.20 | 83.70 | 0.95% |
| CAC 40 | 7,915.36 | 78.13 | -0.98% |
| DAX 40 | 23,409.37 | 181.66 | -0.77% |
| Dow JONES (US) | 47,740.80 | 239.25 | 0.50% |
| FTSE 100 | 10,249.52 | 35.23 | -0.34% |
| HKSE | 25,916.68 | 159.39 | 0.62% |
| NASDAQ | 22,695.95 | 308.27 | 1.38% |
| Nikkei 225 | 54,248.39 | 1,519.67 | 2.88% |
| NZX 50 Index | 13,094.37 | 4.46 | -0.03% |
| S&P 500 | 6,795.99 | 55.97 | 0.83% |
| S&P/ASX 200 | 8,692.60 | 90.30 | 1.05% |
| SSE Composite Index | 4,123.14 | 26.54 | 0.65% |